Juan Jaen Sells 15,764 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 15,764 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $27.73, for a total transaction of $437,135.72. Following the sale, the president directly owned 897,240 shares in the company, valued at $24,880,465.20. This trade represents a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Arcus Biosciences Stock Performance

RCUS stock opened at $30.22 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The company has a 50 day moving average price of $24.67 and a 200 day moving average price of $22.95. Arcus Biosciences, Inc. has a fifty-two week low of $7.91 and a fifty-two week high of $31.44. The stock has a market capitalization of $3.80 billion, a PE ratio of -9.50 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The firm had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The firm’s quarterly revenue was down 39.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.14) EPS. Analysts forecast that Arcus Biosciences, Inc. will post -3.66 EPS for the current year.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds have recently modified their holdings of the business. Hantz Financial Services Inc. grew its position in shares of Arcus Biosciences by 121.9% in the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in Arcus Biosciences during the 4th quarter worth approximately $39,000. KBC Group NV acquired a new stake in Arcus Biosciences during the 1st quarter worth approximately $50,000. Strs Ohio acquired a new stake in Arcus Biosciences during the 1st quarter worth approximately $67,000. Finally, Tower Research Capital LLC TRC lifted its stake in Arcus Biosciences by 184.2% in the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after buying an additional 5,476 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on RCUS. Lifesci Capital started coverage on Arcus Biosciences in a report on Thursday, June 4th. They issued an “outperform” rating and a $46.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a report on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. Morgan Stanley raised their target price on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Monday, May 11th. Finally, Wedbush increased their price objective on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Arcus Biosciences presently has an average rating of “Moderate Buy” and an average price target of $35.10.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.